David Luci Joins MacroChem as General Counsel and Vice President Corporate Development

Wellesley Hills, Massachusetts (ots/PRNewswire) -

- Luci Brings Successful Track Record of Building Value in Biotech
Arena Through Experience in Business Development and Investment
Community Outreach

MacroChem Corporation (OTC Bulletin Board: MACM) has appointed
David P. Luci, Esq. as General Counsel and Vice President Corporate
Development. Mr. Luci will also be Corporate Secretary with
responsibilities encompassing all the company's legal matters
including compliance with securities regulations and corporate
governance. Included in the scope of Corporate Development activities
will be responsibility for partnering activities and investor
relations.

"I'm very pleased to welcome David to MacroChem. Having recently
completed three very important milestones, we are confident that
David's extensive experience will help bolster the company's
continued momentum," stated Robert DeLuccia, President and CEO of
MacroChem. "These key milestones are: last month's announcement of
positive interim Phase 2 data for EcoNail(R) for the treatment of
onychomycosis; the recent acquisition of exclusive worldwide license
rights to pexiganan, a novel topical anti-infective peptide for the
treatment of diabetic foot infection, which has already completed two
Phase 3 trials; and the recent conversion of all preferred shares
into common shares leaving only common stock, warrants, and options
outstanding."

Most recently, Mr. Luci served as Executive Vice President and
General Counsel of Bioenvision where he established the company's
offices in New York, raised over US$75 million in capital, and
advanced Bioenvision stock listing from OTCBB to AMEX and then to
NASDAQ. He was also responsible for garnering analyst interest for a
number of investment firms. While at Bioenvision, he in-licensed the
company's development-stage lead cancer drug for Japan and Southeast
Asia and initiated drug development activities in Japan. He later
successfully guided Bioenvision into a merger agreement and closing
of a related tender offer with its U.S. co-development partner,
Genzyme, in a transaction valued at approximately US$345 million.
Prior to joining Bioenvision, Mr. Luci practiced securities law and
mergers and acquisitions at Paul, Hastings, Janofsky and Walker LLP,
New York. Prior to PHJW, he was Senior Auditor, Ernst and Young, New
York, focused on internal audit and controls within the Mergers and
Acquisitions Practice Group. He is also a member of the Board of
Directors and Chairman of the Audit Committee of Access
Pharmaceuticals, Inc.

"David brings a diverse legal, financial, and business background
as well as excellent knowledge of the biotech sector, both with
pharmaceutical companies and the investment community of our
industry," said Mr. DeLuccia. "His experience includes capital
markets financing, negotiating deals, and license agreements (both
U.S. and ex-U.S.), corporate partnerships, and mergers and
acquisitions. I believe this impressive skill set will serve us well
as we seek to capitalize on our recent achievements and advance our
initiatives in the coming year."

Mr. Luci received his JD, cum laude, from Albany Law School of
Union University, Albany, and his Bachelor of Science in Business
Administration from Bucknell University. He is a member of the New
York Bar Association and a Certified Public Accountant
(Pennsylvania).

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that
develops and seeks to commercialize pharmaceutical products. Our lead
product candidate is EcoNail, a topically applied SEPA-based
econazole lacquer for the treatment of onychomycosis, a condition
commonly known as nail fungus. We recently acquired exclusive
worldwide license rights to pexiganan, a novel topical anti-infective
for the treatment of diabetic foot infection, which has already
completed two Phase 3 trials. Our other clinical stage product
candidate, Opterone(R), is a topically applied SEPA-based
testosterone cream designed to treat male hypogonadism. Our pipeline
of clinical-stage and early-stage product candidates is based on our
SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For
more information visit our website, www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this
press release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection and dependence on third parties for
development and licensing arrangements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. MacroChem undertakes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise. For more information
visit our website, www.macrochem.com.

Contact:
MacroChem: Bernard Patriacca - VP/CFO
+1-781-489-7310
bpatriacca@macrochem.com
Investor Relations: The Investor Relations Group, Inc.
Christine Berni/ Joseph Triunfo, +1-212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
Media:
Bill Douglass/ Michaela Heller, +1-212-825-3210
bdouglass@investorrelationsgroup.com
mheller@investorrelationsgroup.com

Web site: http://www.macrochem.com

ots Originaltext: MacroChem Corporation
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
Bernard Patriacca, VP-CFO of MacroChem Corporation, +1-781-489-7310,
bpatriacca@macrochem.com; or Investor Relations, Christine Berni,
cberni@investorrelationsgroup.com, or Joseph Triunfo,
jtriunfo@investorrelationsgroup.com, +1-212-825-3210, or Media, Bill
Douglass, bdouglass@investorrelationsgroup.com, Michaela Heller,
heller@investorrelationsgroup.com, +1-212-825-3210, all of The
Investor Relations Group, Inc.